About Tudca250:
- TUDCA should be used along with any Pro-Hormone or AAS cycle to reduce stress on the liver and to act as an antioxidant aiding all healthy cells in the body.*
- TUDCA helps in protecting humans from cholestasis (reduction or stoppage of bile flow) because it can break down fats resulting in a healthy liver.*
- TUDCA has been shown by research to improve liver healing rates in both steatotic and non-steatotic livers.*
- TUDCA is helpful in weight loss so it may be beneficial to people with fatty liver or those who want to lose body fat.*
- TUDCA also helps to control cholesterol levels in the liver.*
Modern Warrior TUDCA250 is a water soluble bile acid that shows great potency in treating cholestasis (bile acid backup in the liver) via counteracting the toxicity of regular bile acids. These toxic bile salts can be damaging to cells by destroying the membranes and signaling for cell death. TUDCA 250competes with this toxicity and thus indirectly protect cells from death. TUDCA250 is especially beneficial for those engaged in a strength training program who also take oral performance enhancement products. These products can often inhibit the production and flow of bile from the liver which can have long-term, negative consequences.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
TUDCA:
Tudca (Tauroursodeoxycholic Acid) is a metabolite of Ursodeoxycholic acid (UDCA) and offers optimum liver
health protection specifically for those who have taken, are taking, or plan to take oral performance enhancement
products, which are infamous for inhibiting the production and flow of bile from the liver.
Tudca is the best and most cost-effective option for gainers seeking ultimate liver protection.
Q: What kind of results can I expect from supplementing with TUDCA?
A: TUDCA provides many health-related benefits such as:
• May promote healthy liver function.
• May reverse the toxic effects of metabolites in the liver.
• May eliminate metabolites from the liver more readily.
• May encourage healthy cholesterol levels.
Q: What dosage should I take?
A: As a dietary supplement take 1 Serving (250mg) one or two times daily as needed, or as directed by a medical physician.
Q: What side effects can I expect?
A: TUDCA is produced naturally in the body. There are no known negative side effects from the use of TUDCA.
TUDCA:
1. Crosignani, A., Budillon, G., Cimino, L., Del Vecchio, B. C., Loguercio, C., Ideo, G., … & Podda, M. (1997). Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepato-gastroenterology, 45(23), 1624-1629.
2. Larghi, A., Crosignani, A., Battezzati, P. M., De Valle, G., Allocca, M., Invernizzi, P., … & Podda, M. (1997). Ursodeoxycholic and tauro‐ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary pharmacology & therapeutics, 11(2), 409-414.
3. Crosignani, A., Battezzati, P. M., Setchell, K. D., Invernizzi, P., Covini, G., Zuin, M., & Podda, M. (1996). Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. Digestive diseases and sciences, 41(4), 809-815.
4. Panella, C., Ierardi, E., De Marco, M. F., Barone, M., Guglielmi, F. W., Polimeno, L., & Francavilla, A. (1995). Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease?. The Italian journal of gastroenterology, 27(5), 256-258.
5. Invernizzi, P., Setchell, K. D., Crosignani, A., Battezzati, P. M., Larghi, A., O’Connell, N. C., & Podda, M. (1999). Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine‐conjugated species in patients with primary biliary cirrhosis. Hepatology, 29(2), 320-327.
6. Lindor, K. D., Lacerda, M. A., Jorgensen, R. A., DeSotel, C. K., Batta, A. K., Salen, G., … & Hofmann, A. F. (1998). Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. The American journal of gastroenterology, 93(9), 1498-1504.
